Leveraging Informatics and Modeling Tools to Develop a Comprehensive Design Make and Test Platform
LifeArc, a UK medical research charity focused on developing diagnostics and therapeutics for diseases like cancer and autoimmune disorders, utilizes the Dotmatics Platform to integrate and streamline their entire Design-Make-Test research cycle by uniting internal and external collaborators, automating data acquisition, and providing seamless access to predictive modeling, informatics, and AI/ML tools for small molecule and antibody discovery while protecting intellectual property.
UK-based medical research charity LifeArc is using the Dotmatics Platform and Dotmatics software applications to support their pursuit of next-generation disease diagnostics, treatments, and cures. The company undertakes both small molecule discovery and antibody discovery in hopes of developing groundbreaking diagnostics and therapeutics that will combat conditions such as cancer, Crohn’s disease, multiple sclerosis, and rheumatoid arthritis.
LifeArc chose the Dotmatics Platform and software applications because they can support the company’s entire Design-Make-Test research cycle. With Dotmatics, internal LifeArc chemists and biologists are securely united with external partners from academia, biotech, and CROs on one collaborative research platform. Dotmatics Platform helps the researchers automate data acquisition and gives them seamless access to the predictive modeling, informatics, and AI/ML software they need for small molecule discovery, biologics antibody engineering, and diagnostic testing. With streamlined processes and data that is easy to access, analyze, and visualize, LifeArc scientists essentially have an “Ideas Factory” that helps them not only identify and pursue the most promising design ideas, but also protect their IP and register diverse types of chemical and biologic entities.
“With such an eclectic mix of therapeutic areas and modalities, LifeArc needed an informatics platform that was fit for purpose. We believe that the Dotmatics Platform gives us the flexibility to plug in and play any other tools that we have now or might need in the future,” commented one LifeArc Scientist.
Related
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.
Four Moves Biotechs Can Make to Stay Competitive as Investor Confidence Shifts
As investor confidence in biotech has shifted from rapid, high-risk funding to more cautious, data-driven investment with longer timelines and stricter demands, biotechs must adapt by embracing innovative R&D platforms, demonstrating clear value through validated data and milestones, exploring flexible partnership models like co-development and joint ventures, and strategically managing growth to remain competitive in a market with tighter capital and evolving investor expectations.
From Fragmented Data to Unified Discovery: LifeArc's Approach to Multimodal R&D
LifeArc, a UK-based medical charity focused on transformative life science, has developed a collaborative, multidisciplinary R&D approach that integrates diverse data from over 100 internal scientists, external pharma, biotech, academic partners, and CROs across multiple therapeutic modalities—including small molecules and biologics like engineered antibodies—to streamline drug discovery and design for diseases such as cancer, Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and COVID-19, enabling unified data flow and informed, data-driven decision-making that has already resulted in four licensed medications and several drugs in trials.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.
Trends and Needs in Chemicals and Materials Innovation
Dotmatics’ VP Alister Campbell highlights that despite diverse products, Chemicals and Materials R&D teams face common challenges like regulatory pressures, tight timelines, and budgets, necessitating digitalization strategies focused on quality data management and interoperability to streamline workflows, foster collaboration, and enable AI and machine learning applications that accelerate innovation and maintain competitiveness in this evolving market.
Data Management, Collaboration, and Workflow Optimisation: The Three Keys to Small Molecule Discovery Success
The article emphasizes that despite biologics' prominence, small molecule drug discovery is experiencing a renaissance driven by advances in screening, target exploration, and AI, but overcoming challenges like rising costs, data management, fragmented workflows, and CRO reliance requires success in three key areas: next-generation data management, enhanced cross-disciplinary research collaboration, and workflow optimization.